|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||86.16 - 92.99|
|52 Week Range||46.37 - 137.61|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||16.28|
|Earnings Date||Apr 28, 2021 - May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||118.50|
Robert Kramer, Emergent Biosolutions CEO, joins the Yahoo Finance Live panel to discuss his outlook on COVID-19 as the company manufactures the Johnson & Johnson one-shot vaccine.
Emergent BioSolutions Inc (NYSE: EBS) has built the capacity to produce vaccines from AstraZeneca Plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) around the clock, said CEO Bob Kramer on CNBC. “We are operating at a level where our capacity is well in excess of 1 billion doses annually for those products.” said the CEO. The company bagged a five-year deal with JNJ to produce its COVID-19 vaccine, valued at about $480 million for the first two years. It also entered into a multi-year contract production pact for AstraZeneca’s COVID-19 vaccine. The three-year contract is valued at $174 million through 2021. AZN contract is in addition to an million deal that was announced to secure production space. The J&J vaccine is being produced at Emergent BioSolutions’ Baltimore Bayview facility, one of three Centers for Innovation in Advanced Development and Manufacturing designated by the U.S. government as a rapid vaccine therapeutics manufacturing site. In addition to Emergent BioSolutions, the White House earlier this week arranged a deal with Merck & Co Inc (NYSE: MRK) to help boost J&J’s one-dose vaccine production. President Joe Biden said that he expects the U.S. to have a vaccine supply of 300 million within the next few months, which he says is substantial enough to reach all adults. The projected timeline for building up this supply was also moved to May from the end of July. J&J expects to deliver 20 million shots in the U.S. this month, while a total of 100 million doses are planned for the first half of this year. Price Action: EBS shares closed 4.6% lower at $94.73 on Wednesday. See more from BenzingaClick here for options trades from BenzingaOcugen Shares Are Trading Higher On Its Partner's COVID-19 Vaccine Candidate Showing 81% EfficacyEU Considers Emergency Approvals To Boost COVID-19 Vaccine Rollout: Reuters© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
A break in a key support level could precipitate further declines in the life sciences company's shares.